Momentum continues in the #HIV R&D pipeline— with two early-phase #Vaccine trials, a late-phase monthly #PrEP pill, and advancing #HIVcure research. Stay current on the science shaping prevention and cure in #PxWire:
The latest issue of #PxWire showcases how access to #LEN for PrEP is accelerating—and why its delivery is moving faster than any #PrEP product before it.
Hot off the presses! The #PEPFAR stopwork order resulted in major declines in #PrEPAccess. Our latest issue of #PxWire shows the impact, country by country, with significant declines to life-saving #PrEP. #DeadlyPause buff.ly/tC66sCu
Momentum continues in the #HIV R&D pipeline— with two early-phase #Vaccine trials, a late-phase monthly #PrEP pill, and advancing #HIVcure research. Stay current on the science shaping prevention and cure in #PxWire: buff.ly/tC66sCu
The latest issue of #PxWire showcases how access to #LEN for #HIV PrEP is accelerating—and why its delivery is moving faster than any #PrEP product before it. buff.ly/tC66sCu
The #PEPFAR stopwork order resulted in major declines in #PrEPAccess. Our latest issue of #PxWire shows the impact, country by country, with significant declines to life-saving #PrEP. #DeadlyPause buff.ly/tC66sCu
The latest #PxWire tracks where oral #PrEP access stands after the #ForeignAid Freeze. From an accelerated process for delivering #LEN for #PrEP to new vaccine trials for #HIVPrevention, this issue tracks and translates the HIV prevention pipeline from research to rollout. buff.ly/tC66sCu
Generic #lenacapavir (LEN) for #PrEP could become available in 2027 in up to 120 countries. Track the rollout of long-acting #HIVPrEP at www.prepwatch.org/long-acting-...
#PxWire #HIVprevention
Our new #PxWire issue is out! It tracks funders & countries rolling out new #PrEP products; compares their prices; and shows sites launching the 1xmonth pill.
Read it all here: avac.org/pxwire/
@eltonjohnaidsfoundation.org @ciffchild.bsky.social @gatesfoundation.bsky.social @unitaid.bsky.social